Latest:
Dr Possik on the Importance of Diversity and Equity in Melanoma Research
Patricia A. Possik, PhD, discusses the importance of efforts to improve diversity, equity, and inclusion in melanoma research.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Bruno R. Bastos, MD, Miami Cancer Institute
Latest:
Looking at Novel Treatments in Lung and Genitourinary Cancers From ESMO 2023: Drs Janne and Bastos
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Paul Stockhammer, MD, PhD
Latest:
Dr Stockhammer on Gene Alterations and Poor Outcomes in EGFR-Mutant Lung Cancer
Paul Stockhammer, MD, PhD, discusses research into the association between alterations in multiple tumor suppressor genes and poorer outcomes in patients with EGFR-mutant lung cancer, which was presented at the 2023 ASCO Annual Meeting.
Benjamin Miron, MD
Latest:
Dr Miron on the Methods of Examining Molecular Alterations in Intraductal Carcinoma of the Prostate
Benjamin Miron, MD, discusses the methods utilized in a study of molecular alterations in patients with intraductal carcinoma of the prostate and the next steps for this research.
Liat Hogen, MD, FRCSC
Latest:
Dr Hogen on Survival Outcomes With Neoadjuvant Chemotherapy and ICS in Epithelial Ovarian Cancer
Liat Hogen, MD, FRCSC, discusses the survival outcomes achieved with interval cytoreductive surgery following neoadjuvant chemotherapy in a study of patients with initial unresectable stage IV ovarian cancer.
Yoshiaki Nakamura, MD, PhD
Latest:
Concluding Remarks for the Current Use of ctDNA Testing for Treatment Decisions in stage II-III CRC
Yoshiaki Nakamura, MD, PhD, discusses the quantification threshold for tissue-free ctDNA in detecting residual tumor fractions, highlights additional mutations and hypermethylated loci identified by epigenomic assays, and examines how these assays complement current radiographic monitoring in stage II to III CRC while also considering their evolving role in identifying MRD to enhance recurrence-free survival.